SFO
WST icon

Standard Family Office’s West Pharmaceutical WST Stock Holding History

Standard Family Office’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-240
Closed -$59K – 454
2022
Q3 		$59K Buy
+240
New +$73.1K 0.03% 114
2022
Q2 		– Sell
-395
Closed -$162K – 264
2022
Q1 		$162K Buy
+395
New +$155K 0.04% 17
2021
Q3 		– Sell
-424
Closed -$152K – 525
2021
Q2 		$152K Hold
424
– – 0.03% 175
2021
Q1 		$119K Buy
424
+11
+3% +$3.15K 0.03% 180
2020
Q4 		$117K Buy
+413
New +$116K 0.03% 177

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Standard Family Office's WST Position: Q4 2022 in Review

Standard Family Office sold out of West Pharmaceutical (WST) in Q4 2022, closing a stake of 240 shares — an estimated $59K sold.

Standard Family Office first reported a position in WST in Q4 2020 and held it in 5 quarters. The position peaked at $162K in Q1 2022. 637 funds tracked by Wall St. Rank hold WST as of Q4 2022.

  • Standard Family Office reported no remaining West Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Standard Family Office sold 240 West Pharmaceutical shares in Q4 2022, an estimated $59K.
  • Standard Family Office first reported a position in West Pharmaceutical in Q4 2020 and held it in 5 quarters.
  • Standard Family Office's West Pharmaceutical position peaked at $162K in Q1 2022.
  • 637 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.